---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000813569.md"
description: "📢 𝗝𝗨𝗦𝗧 𝗜𝗡: Eli Lilly Delays Retatrutide Approval Filing to Q1 2027 - $Eli Lilly(LLY.US) $Hims & Hers Health(HIMS.US) $Novo Nordisk AS(NVO.US) 👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:➤  𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 plans to file for 𝗿𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲 approval in 𝗤𝟭 𝟮𝟬𝟮𝟳.➤  Filing delayed to gather additional 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 and quality-control data.➤  Phase 3 trials met primary endpoints in two additional studies.➤  Adults with obesity and Type 2 diabetes lost up to 𝗮𝗻 𝗮𝘃𝗲𝗿𝗮𝗴𝗲 𝗼𝗳 𝟮𝟬.𝟴% body weight.➤  Adults with severe obesity and cardiovascular disease lost up to 𝗮𝗻 𝗮𝘃𝗲𝗿𝗮𝗴𝗲 𝗼𝗳 𝟮𝟮.𝟲% body weight.➤  Retatrutide targets 𝗚𝗟𝗣-𝟭, 𝗚𝗜𝗣, and 𝗴𝗹𝘂𝗰𝗮𝗴𝗼𝗻 hormones.➤  Common side effects included 𝗱𝗶𝗮𝗿𝗿𝗵𝗲𝗮, 𝗻𝗮𝘂𝘀𝗲𝗮, and 𝗰𝗼𝗻𝘀𝘁𝗶𝗽𝗮𝘁𝗶𝗼𝗻.➤  TD Cowen estimates retatrutide could generate $𝟯.𝟴 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 in 𝟮𝟬𝟯𝟬 sales.➤  Novo Nordisk recently sued Lilly over 𝗮𝗹𝗹𝗲𝗴𝗲𝗱 false advertising claims.👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁:𝗞𝗲𝗻𝗻𝗲𝘁𝗵 𝗖𝘂𝘀𝘁𝗲𝗿, President of Lilly Cardiometabolic Health:"We believe we have the information necessary to file for approval globally for retatrutide as a potential treatment for obesity, knee osteoarthritis pain and obstructive sleep apnea.""
datetime: "2026-07-23T14:55:50.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000813569.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000813569.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000813569.md)
author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)"
generator: "portal-rs"
---

# 📢 𝗝𝗨𝗦𝗧 𝗜𝗡: Eli Lilly Delays Retatrutide Approval F…


### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**